New ADC homes in on Trop-2 glycoprotein to target cancer cells
Immunomedics has developed an antibody drug conjugate (ADC) called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to triple negative breast cancer (TNBC) tumours, which highly express the glycoprotein Trop-2 and represents an unmet need within a highly treated cancer type.
GlobalData’s pharmaceutical technology writer Allie Nawrat says: “The New Jersey-based firm has developed a novel ADC platform centred around its specialised hydrolysable linker, which delivers potent chemotherapy metabolites directly to cancer tumour sites and their microenvironments.
“Immunomedics’ lead candidate, sacituzumab govitecan, is currently being developed for heavily treated TNBC patients. The company has received US Food and Drug Administration breakthrough designation and recently re-submitted its biologics license application for the drug in this indication.”
Immunomedics chief commercial officer Brendan Delaney explains: “We decided to focus on TNBC because of the level of unmet medical need that exists here. Our ADC technology really strongly aligns with the biology of TNBC. It targets Trop-2, which happens to be highly expressed on the surface of TNBC cells. It’s a highly attractive target and it’s able to internalise an antibody drug conjugate pretty quickly.
“Because Trop-2 is overexpressed, sacituzumab govitecan is able to deliver SN-38, which is the active metabolite of chemotherapy irinotecan, directly to the tumour.
“Our linker allows the cytotoxic payload to stay bound to the monoclonal antibody – in this case Trop-2 – as it finds its way to Trop-2 expressing tumours. Once the ADC is docked at the binding site on the tumour cell, SN-38 is taken into the cell, where the payload is released and has its cell kill effect, but because of the hydrolysable linker, some of that payload comes off on the outside of the cell, [creating] a pretty substantial bystander effect in the tumour micro-environment.”
“In the future, we have hopes to explore every tumour type where Trop-2 has any expression. This includes non-small cell lung cancer where we are enrolling a clinical trial currently – the Tropics-03 trial. It’s a basket trial looking at different expression levels of Trop-2 in various patients.”
For more information
Visit GlobalData’s Verdict
To gain access to our latest press releases: GlobalData Media Centre
Please contact the GlobalData Press Office for comment:
EMA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809
Email: [email protected]
For expert analysis on developments in your industry, please connect with us on:
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make timelier and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.